13/05/2016 (Esclerosis sistemica, compromiso gastrointestinal, reflujo, vaciamiento gástrico)

En los pacientes con esclerosis sistémica que presenta compromiso gastrointestinal ¿que estrategia terapéutica es recomendable?

Contexto

En los pacientes con esclerosis sistémica los hallazgos pulmonares y cutáneos son los objetivos de tratamiento, quisieramos saber si existe evidencia en el desenlace gastrointestinal.

Pregunta PICO

  • P: Pacientes con esclerosis sistémica con compromiso gastrointestinal
  • I: Terapia específica dirigida a compromiso gastrointestinal
  • C: terapia convencional
  • O: Mejoria en compromiso gastrointestinal

Búsqueda

definidad individualmente segun pico

Búsqueda

definida individualmente segun pico sugiero: (((gastr*[Title]) OR intestinal[Title])) AND systemic sclerosis[Title] 

Artículos Propuestos

Proponente Referencia Ver/Descargar
Ruben Guillermo Jaramillo. [3 de mayo de 2016, 14:10] Ariyasu H, Iwakura H, Yukawa N, Murayama T, Yokode M, Tada H, et al. Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis. Endocr J. 2014;61(7):735–42.

Renan Morales. [3 de mayo de 2016, 18:58] Jasmin Raja, Svetlana I. Nihtyanova, Charles D. Murray, Christopher P. Denton,and Voon H. Ong Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis Rheumatology (2016) 55 (1): 115-119
Alex Casallas [9 de mayo de 2016, 08:50] Gyger G, Baron M. Systemic Sclerosis: Gastrointestinal Disease and Its Management. Rheumatic diseases clinics of North America. 2015;41(3):459-73.

Alex Casallas [9 de mayo de 2016, 08:55] Hansi N, Thoua N, Carulli M, Chakravarty K, Lal S, Smyth A, et al. Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clinical and experimental rheumatology. 2014;32(6 Suppl 86):S-214-21.
Eybar Alfonso Díaz Ibarra [9 de mayo de 2016, 13:52] Guo, L., Chen, X. X., Gu, Y. Y., Zou, H. J., & Ye, S. (2012). Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review. Clinical rheumatology, 31(9), 1395-1400.
Jorge Abella [9 de mayo de 2016, 14:28] Lorenzi A, Johonson H, Davies G, Gough A. Gastric antral vascular ectasia in systemic sclerosis: complete resolution with methylprednisolone and cyclophosphamide. Ann Rheum Dis 2001;60:796–798
Jorge Abella [9 de mayo de 2016, 14:37] Schulz S, O´Brien M, Maqsood M, Sandorfi N, Del Galdo F, Jimenez S. Improvement of Severe Systemic Sclerosis-associated Gastric Antral Vascular Ectasia Following Immunosuppressive Treatment with Intravenous Cyclophosphamide. J Rheumatol 2009;36;1653-1656
Javier Cajas [10 de mayo de 2016 07:00] Savarino E, Furnari M, de Bortoli N, Martinucci I, Bodini G, Ghio M, et al. Gastrointestinal involvement in systemic sclerosis. Presse medicale (Paris, France : 1983). 2014;43(10 Pt 2):e279-91.
Yimy Medina [10 de mayo de 2016, 7:49] Nagaraja V, McMahan ZH, Getzug T, Khanna D. Management of gastrointestinal involvement in scleroderma. Current treatment options in rheumatology. 2015;1(1):82-105.
Edwin Tellez [10 de mayo de 2016, 7:38] Sallam HS, McNearny TA, Chen JD.  Acupuncture-based modalities: novel alternative approaches in the treatment of gastrointestinal dysmotility in patients with systemic sclerosis. Explore (NY). 2014;10(1):44-52.
Juan David Jiménez [10 de mayo de 2016, 18:25] Kato R, Nakajima K, Takahashi T, Miyazaki Y, Makino T, Kurokawa Y, et al. A case of advanced systemic sclerosis with severe GERD successfully treated with acotiamide. Surgical Case Reports. 2016;2(36):1-5.
Juan Duarte [11 de mayo de 2016, 0:47] Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol. 2007 Jun;13(3):119-23

Puntos clave/Conclusiones

Tratar toda la enfermedad no el intestino solo.